Lv41
740 积分 2024-03-05 加入
PILRα on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity
12天前
已完结
Structure-Activity Studies of Interleukin-2
1个月前
已完结
T cell activation and effector function in the human Jurkat T cell model
1个月前
已完结
Integrating immunotherapy in the treatment of resectable gastric cancer: Are we on the right track?
1个月前
已完结
Functional differences between rodent and human PD-1 linked to evolutionary divergence
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
T cell-engaging therapies — BiTEs and beyond
3个月前
已完结
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
3个月前
已完结
皖公网安备34019202002308
